Inhaled antiseptics and inhaled antiviral non-prescription drugs in the prevention of ARVI, in particular COVID-19: an epidemiological study

Yu.I. Feshchenko¹, M.I. Gumeniuk¹, M.I. Lynnyk¹, O.Ya. Dziublyk¹, M.M. Kuzhko¹, O.V. Tereshkovych¹, O.V. Khmel¹, I.O. Panashchuk¹, M.V. Yashchenko², O.S. Denysov³, T.A. Sprynsian³

- 1. SI "National institute of phthisiology and pulmonology named after F.G. Yanovsky of the NAMS of Ukraine", Kyiv, Ukraine
- 2. Pharmaxi LLC, Kyiv, Ukraine
- 3. Association for Intensive Care of Infectious Diseases (INCURE), Kyiv, Ukraine

Conflict of interest: none

ACKGROUND. The article presents the results of a continuous, cross-sectional, non-interventional, multicenter retrospective epidemiological study, which included cases of 3443 participants. Questionnaires and rapid test for antibodies to SARS-CoV-2 were used to collect data.

OBJECTIVE. To determine the relationship between the systematic use of additional drugs for the prevention of COVID-19, including inhaled antiseptics and inhaled antiviral drugs, separately and in combination with other drugs, and the risk of developing of coronavirus disease (COVID-19).

RESULTS AND DISCUSSION. 396 participants (11.8 %) took inhaled antiseptics in any period since March 2020, and 410 participants (12.2 %) took inhaled antivirals. A statistically significant protective relationship between episode of COVID-19 when taking inhaled antiseptics and inhaled antiviral drugs (risk ratio 0.901; 95 % confidence interval 0.856-0.948) was determined.

CONCLUSIONS. The use of inhaled antiseptics and inhaled antiviral drugs as additional methods of prevention of COVID-19 has shown a statistically significant effect not only on reducing the risk of COVID-19, but different combinations of inhaled antiseptics or inhaled antiviral drugs with other drug groups as additional methods of preventing COVID-19 had a statistically significant protective relationship with the episode of the disease, with the severity of COVID-19 and with the need for hospitalization.

KEY WORDS: inhaled antiseptics, inhaled antiviral drugs, coronavirus infection, prevention of infectious diseases, non-prescription drugs, epidemiological research.

DOI: 10.32902/2663-0338-2021-4-5-15